Response Genetics Triples Sales Force on Growing Demand for Lung, Colon Cancer Dxs

The firm plans to increase its marketing team to 10 reps by the end of the month after selling 500 ResponseDX tests for lung and colon cancer since last September.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.